Table S1.
Characteristics of cohort studies included in meta-analyses
| Study, country | EGFR-TKIs; n (%) as first line | Population; clinical stage | Pathological type (n) | Specimen; method | BIM deletion rate, n (%) | ORR, n (%) | Median PFS (months, with vs without BIM deletion) | Median OS (months, with vs without BIM deletion) | Adjusted covariates for hazard ratio |
|---|---|---|---|---|---|---|---|---|---|
| Ng et al,1 Singapore, Japan | Gefitinib or erlotinib; 93 (66.0) | Patients with EGFR- NSCLC; III/IV/recurrent | AC (128); BAC (4); others (9); total (141) | Peripheral blood or biopsy slides and blocks; DNA polymorphism | 26 (18.4) | NR | 6.6 vs 11.9 | NR | Age, gender, histology, smoking history, type of EGFR mutation by exon and specific mutation, stage, first- or second-line TKI therapy, race, country, TKI type and ECOG status |
| Lee et al,2 Korea | Gefitinib or erlotinib; 67 (34.0) | Patients with NSCLC harboring EGFR- activating mutations; IIIB/IV/postoperative relapse | AC (191); ASC (1); NSCLC, NOS (5); total (197) | Tumor tissue; DNA polymorphism | 21 (10.9) | 154 (77.7) | 11.9 vs 11.3 | NR | NR |
| Zheng et al,3 People’s Republic of China | Gefitinib or erlotinib; 0 | Patients with advanced NSCLC; IIIB/IV | AC (97); others (26); total (123) | Peripheral blood; DNA polymorphism | 21 (17.1) | 36 (29.3) | 3.5 vs 6.0 | NR | Age, gender, histology, smoking history, stage, line of TKI therapy, TKI type and performance status |
| Costa et al,4 European | Erlotinib; 50 (100) | Patients with advanced EGFR-mutation- positive NSCLC; IIIB (malignant effusion)/IV/unknown (n=1) | AC (47); others (3); total (50) | Tumor tissue; mRNA expression | Low (<1.83) or intermediate (1.83–2.96) in 53 (64.0) and high (≥2.96) in 30 (36.1) | 28 (56.0) | 7.2 vs 12.9 | 20.8 vs 24.5 | Potential risk factors as covariates |
| Zhong et al,5 People’s Republic of China | Gefitinib or erlotinib; overall 35.5% | Patients with advanced EGFR-mutation-positive NSCLC; overall – IIIa (4.5); IIIb (7.6); IV (78.7) | AC (159) | Patient blood samples; DNA polymorphism | Overall, 15.5% | Overall, 24.5% | 7.3 vs 9.5 | 21.9 vs 21.9 (overall) | NR |
| Isobe et al,6 Japan | Gefitinib or erlotinib; 70 (100) | Patients with EGFR-mutation-positive NSCLC; IV/recurrent | AC (65); SCC (7); total (72) | Peripheral blood; DNA polymorphism | 18.6 | 64.30 | 7.5 vs 17.6 | 38.9 vs 45.1 | Sex, bone metastasis and smoking history |
| Zhao et al,7 People’s Republic of China | Gefitinib or erlotinib; 69 (41.6) | Patients with activating EGFR mutations – NSCLC; IIIB/IV | AC (140); SCC (8); ASC (9); others (9); total (166) | Tumor tissue; DNA polymorphism | 9.6 | 62.0 | 4.7 vs 11.0 | NR | Age, gender and exon 19 deletion vs L858R |
| Lee et al,8 People’s Republic of China | Gefitinib, erlotinib and afatinib; overall 153 (75) | Patients with activating EGFR mutations – NSCLC; IIIB/IV | Overall: AC (189); non-AC (12); unspecified (3) | Peripheral blood; DNA polymorphism | 20.0 | 51.0 | 7.4 vs 9.4 | 18.3 vs 24.9 | Age, gender, EGFR mutation and non-AC |
| Lee et al,9 Korea | Gefitinib or erlotinib; 68 (33) | Patients with EGFR-mutant NSCLC who received EGFR-TKIs; IIIB/IV/postoperative relapse | AC (203); SCC (2); total (205) | Peripheral blood; DNA polymorphism | 15.6 | 85.0 | 11.9 vs 10.9 | 31.2 vs 30.3 | Age, gender, smoking history, performance status, pathology, stage, number of metastases, type of EGFR mutation, EGFR-TKIs type, and line of EGFR-TKIs |
| Present study, People’s Republic of China | Gefitinib or erlotinib; 54 (38.6) | Patients with EGFR-mutant NSCLC who received EGFR-TKIs; IIIB/IV | AC (128); others (12); total (140) | Peripheral blood; DNA polymorphism | 26.4 | 56.4 | 20.6 vs 17.0 | 34.2 vs 33.0 | None; prespecified subgroup analyses done |
Abbreviations: AC, adenocarcinoma; ASC, adenosquamous carcinoma; BAC, bronchioalveolar carcinoma; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; NR, not reported; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SCC, squamous cell carcinoma; TKIs, tyrosine kinase inhibitors.